| Literature DB >> 32715671 |
Jangmi Yang1, Miyoung Choi1, JinA Choi1, Minjoo Kang1, AeJung Jo1, Seung Hyun Chung2, Sung Hoon Sim2, Yu Jung Kim3, Eun Joo Yang1,4, Su Yeon Yu5.
Abstract
BACKGROUND: As the survival rate of cancer patients increases, the clinical importance of rehabilitation provided by healthcare professionals also increases. However, the evidence supporting the relevance of rehabilitation programs is insufficient. This study aimed to review the literature on effectiveness in physical function, quality of life (QOL) or fatigue of supervised physical rehabilitation in patients with advanced cancer.Entities:
Keywords: Exercise; Neoplasm; Rehabilitation; Systematic review
Mesh:
Substances:
Year: 2020 PMID: 32715671 PMCID: PMC7384905 DOI: 10.3346/jkms.2020.35.e242
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Definition of mean difference
| Intervention-control study | Before-after study |
|---|---|
| Mean difference = ( | Mean difference = |
A = mean in intervention group, B = mean in control group, t1 = after exercise, t0 = before exercise, D = mean in post-exercise group, D = mean in pre-exercise group.
Fig. 1Flow diagram for identification of eligible studies.
P = patient, I = intervention, C = comparator, O = outcome.
Characteristics of included studies
| First author, year, country | Study design/No. of participants (drop out) | Classified study types | Age, mean (SD or range) | Cancer type, No. (%) | Status | Intervention | Outcomes | ||
|---|---|---|---|---|---|---|---|---|---|
| When | Where/by whom | How | |||||||
| Jastrzębski, 2015, Poland | RS/pulmonary rehabilitation: 12 (5) vs. no exercise: 12 (0) | Intervention–control | 59.0 (7) | Lung (100) | Stage III or IV; earlier stage but unsuitable for surgery or radiation | On chemotherapy | Hospital/not reported | Four 2-week rehabilitation cycles including Nordic Walking, aerobic exercises and respiratory exercises, etc. | Cardiovascular endurance, quality of life, pulmonary function, others |
| Jensen, 2014, Germany | RS/resistance: 13 (2) vs. aerobic: 13 (3) | 1. Before–after (resistance) | 55.0 (13.1) | Colon (28.6), Cholangiocellular (19.0), rectal (23.8), etc. | Metastases in other organs | On palliative chemotherapy | Outpatients clinic/not reported | 1. Resistance: 45 min, twice a week, 24 sessions over 12 weeks | Physical activity, strength, quality of life, others |
| 2. Before–after (aerobic) | 2. Aerobic: 45 min on a bicycle ergometer twice a week for 12 weeks | ||||||||
| Rief, 2014, Germany | RS/resistance: 30 (0) vs. passive physical therapy: 30 (0) | Intervention–control | I: 61.3 (10.1) | Lung (33.3), prostate (23.3), breast (18.3), etc. | Metastases in spinal bone | On radiotherapy | Hospital/physiotherapist | 30 min, 5 days per week for the two-week RT period | Pain |
| C: 64.1 (10.9) | |||||||||
| Cormie, 2013 Australia | RS/resistance: 10 (2) vs. usual care: 10 (3) | Intervention–control | I: 73.1 (7.5) | Prostate (100) | Metastases in bone | On medication | Exercise clinic/accredited exercise physiologist | 60 min, twice-weekly sessions for 12 weeks | Physical activity, cardiovascular endurance, physical performance, strength, balance, quality of life, pain, fatigue, others |
| C: 71.2 (6.9) | |||||||||
| Litterini, 2013, USA | RS/cardiovascular exercise: 32 (3) vs. resistance: 34 (11) | 1. Before–after (cardiovascular exercise) | 62.4 (13.5) | Breast (21.2), colorectal (13.6), lung (16.7), etc. | Metastases in other organs | On chemotherapy (36.4), chemotherapy and radiotherapy (28.8), none (16.7), etc. | Hospital-based fitness facility/oncology-trained exercise specialists (a doctor of physical therapy, personal trainers) | 1. Cardiovascular: 30–60 min, twice weekly for 10 weeks with bicycle, treadmill, Nustep (TRS 4000), etc. | Physical performance, pain, fatigue |
| 2. Before–after (resistance) | 2. Resistance: 30–60 min, twice weekly for 10 weeks with Circuit weight training equipment, etc. | ||||||||
| Oldervoll, 2011, Norway | RS/physical exercise: 121 (43) vs. usual care: 110 (25) | Intervention–control | I: 62.6 (11.3) | Gastrointestinal (31.6), breast (22.0), lung (16.5), etc. | Incurable and metastatic cancer | On chemotherapy (20.7), hormonal therapy (17.4), radiotherapy (7.4), etc. | Outpatient clinic/physiotherapist | 50–60 min, two exercise sessions per week for an 8-week with circuit training and stretching and relaxation | Cardiovascular endurance, physical performance, strength, fatigue |
| C: 62.2 (10.7) | |||||||||
| Loughney, 2017, UK | NRS/exercise: 23 (0) vs. usual care: 10 (0) | Before–after (exercise) | 64.0 (45–82) | Rectal | Locally advanced, no distant metastasis | Between neoadjuvant chemotherapy and surgery | Hospital/not reported | 40 min, 3 sessions per week for a 6-week | Physical activity |
| Quist, 2015, Denmark | NRS/group training: 114 (43) | Before–after | 66.0 (31–88) | Lung | Stage IIIb–IV | On chemotherapy | Hospital/research physiotherapist | 90 min, twice weekly for a 6-week with cycling and strength training | Cardiovascular endurance, strength, quality of life, pulmonary function, others |
| Beydoun, 2014, Australia | NRS/at home exercise: 255 (30), face to face exercise: 396 (17), man plan support: 208 (28) | Before–after (face to face exercise) | 71.0 (8) | Prostate (100) | Relapsed or metastatic | On androgen deprivation therapy | Hospital/accredited exercise physiologist | A 10-week exercise programme consisting of two group sessions per week | Cardiovascular endurance, strength, physical performance, others |
| Cormie, 2014, Australia | NRS/resistance: 20 (5) | Before–after | 70.0 (9.8) | Prostate (85.0), breast cancer (15.0) | Metastases in bone | On medication | Exercise clinic/accredited exercise physiologist | 60 min, twice-weekly sessions for 12 weeks | Physical activity, cardiovascular endurance, physical performance, strength, balance, quality of life, pain, fatigue, others |
| van den Dungen, 2014, Netherland | NRS/exercise: 26 (4) | Before–after | 54.5 (8.9) | Breast (26.9), gastrointestinal (30.8), other (42.3) | Incurable metastasized, recurrent or progressive | On palliative anticancer therapy | Physical therapy center/physical therapist | 12-min, twice-weekly for a 6-week, resistance and aerobic interval training | Cardiovascular endurance, strength, quality of life, fatigue, others |
SD = standard deviation, C = comparator, I = intervention, NRS = non-randomized study, RS = randomized study.
Result of meta-analysis
| Outcome | Type | Measurement | Included studies | No. of I (A)/C (B) | Hetero geneity | Mean difference (95% CI) | |||
|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | |||||||||
| Primary outcomes (physical function) | |||||||||
| Physical activity | BA | Total energy expenditure (kcal/day) | Jensen et al. | 44/49 | 0 | 0.74 | 88.22 (−92.64, 269.08) | 0.34 | |
| BA | Step count (n/day) | 58 | 0.12 | 13.04 (−5.31, 31.39) | 0.16 | ||||
| BA | MET | 0 | 0.79 | 0.29 (0.07, 0.51) | 0.01 | ||||
| BA | Sleep duration (h/day) | 8 | 0.30 | 0.60 (−0.04, 1.23) | 0.07 | ||||
| BA | Lying down (h/day) | 0 | 0.95 | 0.23 (−1.00, 1.46) | 0.72 | ||||
| Physical performance (SPPB) | BA | Total score | Litterini et al. | 52/66 | 0 | 0.85 | 0.60 (−0.15, 1.36) | 0.12 | |
| BA | Balance score | 0 | 0.90 | 0.16 (−0.06, 0.39) | 0.15 | ||||
| BA | Gait score | 0 | 0.75 | 0.12 (−0.10, 0.34) | 0.28 | ||||
| BA | Chair stands score | 0 | 0.72 | 0.31 (−0.16, 0.78) | 0.20 | ||||
| Strength | BA | Leg press (kg) | Cormie et al. | 119/130 | 0 | 0.41 | 12.18 (6.00, 18.35) | 0.0001 | |
| BA | Knee extensor (kg) | Jensen et al. | 82/44 | 0 | 0.35 | 2.43 (−0.45, 5.31) | 0.10 | ||
| BA | Bench press (kg) | Quist et al. | 93/97 | 0 | 0.78 | 4.81 (0.85, 8.77) | 0.02 | ||
| BA | Abdominal crunch (kg) | 0 | 0.81 | 6.48 (2.01, 10.96) | 0.005 | ||||
| BA | Back (kg) | Jensen et al. | 82/44 | 0 | 0.74 | 5.17 (1.60, 8.75) | 0.005 | ||
| Cardiovascular endurance | BA | 6MWD (m) | Quist et al. | 93/97 | 0 | 0.92 | 32.60 (−3.13, 68.34) | 0.07 | |
| Pain | IC | VAS (cm) | Cormie et al. | 40/40 | 0 | 0.32 | −0.32 (−1.20, 0.56) | 0.48 | |
| BA | VAS (cm) | Cormie et al. | 67/86 | 0 | 0.70 | −0.02 (−0.61, 0.56) | 0.93 | ||
| Secondary outcomes (QOL, fatigue) | |||||||||
| QOL (SF-36) | IC | Physical function | Cormie et al. | 22/18 | 0 | 0.96 | 0.32 (−10.30, 10.94) | 0.95 | |
| IC | Role physical | 0 | 0.41 | 3.06 (−8.25, 14.37) | 0.60 | ||||
| IC | Bodily pain | 0 | 0.96 | −2.27 (−12.52, 7.98) | 0.66 | ||||
| IC | General health | 0 | 0.92 | −0.90 (−10.09, 8.28) | 0.85 | ||||
| IC | Vitality | 0 | 0.61 | 7.68 (−4.73, 20.10) | 0.23 | ||||
| IC | Social functioning | 0 | 0.32 | 3.52 (−6.36, 13.39) | 0.49 | ||||
| IC | Role emotional | 0 | 0.79 | 5.20 (−6.80, 17.19) | 0.40 | ||||
| IC | Mental health | 0 | 0.74 | 3.45 (−6.93, 13.83) | 0.51 | ||||
| IC | Physical health composite | 0 | 0.88 | 0.56 (−8.78, 9.90) | 0.91 | ||||
| IC | Mental health composite | 0 | 0.81 | 1.91 (−9.31, 13.14) | 0.74 | ||||
| BA | Physical function | Cormie et al. | 37/46 | 0 | 0.77 | 2.33 (−2.90, 7.57) | 0.38 | ||
| BA | Role physical | 0 | 0.52 | 2.98 (−3.39, 9.34) | 0.36 | ||||
| BA | Social functioning | 0 | 0.76 | 3.19 (−1.99, 8.37) | 0.23 | ||||
| BA | Vitality | 0 | 0.42 | 3.27 (−2.18, 8.71) | 0.24 | ||||
| QOL (EORTC-QLQ-30) | BA | Global health status/QOL | Jensen et al. | 43/52 | 0 | 0.58 | 10.28 (2.53, 18.02) | 0.009 | |
| BA | Physical functioning | 0 | 0.98 | 2.74 (−1.47, 6.96) | 0.20 | ||||
| BA | Role functioning | Jensen et al. | 21/26 | 0 | 0.72 | 18.83 (5.20, 32.46) | 0.007 | ||
| BA | Emotional functioning | 0 | 0.64 | 8.95 (−5.69, 23.59) | 0.23 | ||||
| BA | Cognitive functioning | 0 | 0.35 | 7.15 (−8.52, 22.81) | 0.37 | ||||
| BA | Social functioning | Jensen et al. | 43/52 | 0 | 0.80 | 6.62 (−3.01, 16.25) | 0.18 | ||
| BA | Fatigue | 50 | 0.13 | −15.21 (−28.46, −1.97) | 0.02 | ||||
| BA | Nausea, vomiting | Jensen et al. | 21/26 | 0 | 0.91 | −1.24 (−13.26, 10.78) | 0.84 | ||
| BA | Pain | 0 | 0.60 | 1.49 (−16.59, 19.56) | 0.87 | ||||
| BA | Dyspnoea | 0 | 0.75 | −5.26 (−22.47, 11.95) | 0.55 | ||||
| BA | Insomnia | 0 | 0.86 | −5.90 (−21.21, 9.40) | 0.45 | ||||
| BA | Appetite loss | 0 | 0.61 | −5.33 (−22.84, 18.18) | 0.66 | ||||
| BA | Constipation | 0 | 1.00 | 0.00 (−10.92, 10.92) | 1.00 | ||||
| BA | Diarrhoea | 0 | 0.84 | −8.24 (−27.61, 11.13) | 0.40 | ||||
| BA | Financial difficulties | 0 | 0.42 | −0.76 (−22.92, 21.40) | 0.95 | ||||
| Fatigue | BA | VAS (mm) | Litterini et al. | 96/118 | 0 | 0.76 | −4.67 (−10.38, 1.04) | 0.11 | |
6MWD = 6-minute walk distance, A = after, B = before, BA = before-after study, C = comparator, CI = confidence interval, EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer quality of life questionnaire version C30, ESAS = Edmonton Symptom Assessment System, I = intervention, IC = intervention-comparator study, MET = metabolic equivalent of task, SF-36 = 36-item Short-Form Health Survey, SPPB = Short Physical Performance Battery, VAS = visual analogue scale, QOL = quality of life.
Fig. 2Forest plot of “strength”.
CI = confidence interval.
Fig. 3Forest plot of “MET”.
CI = confidence interval, MET = metabolic equivalent of task.
Fig. 4Forest plot of “QOL”.
QOL = quality of life, CI = confidence interval, EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer quality of life questionnaire version C30.